Purpose We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by ...
Avoidance of concomitant medications known to decrease CYP2D6 activity might improve outcomes for patients with the wild-type genotype, but we are left with the question of what the best treatment ...
Breast cancer treatment has increasingly integrated pharmacogenomic insights to tailor therapies according to patients’ genetic profiles, thereby optimising treatment outcomes and minimising adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results